Roche Suspends Future Investments in Germany Amid Political and Regulatory Concerns

Pharmaceutical giant Roche has announced a temporary halt to all future investments in Germany, citing a loss of trust in the German government's healthcare policies. Daniel Steiners, head of Roche in Germany, revealed in an interview that the decision reflects a strategic reassessment prompted by recent political developments and regulatory challenges, particularly criticizing the new GKV contribution stabilization law. Steiners emphasized that this law burdens the pharmaceutical sector without addressing the structural problems within the healthcare system, focusing instead on short-term savings.

Roche, which has operated in Germany for 130 years, is at a pivotal moment, with Steiners highlighting that the company can no longer assume uninterrupted investment in the country. The firm is considering investment opportunities beyond Germany, including in the United States and China, as Europe faces stiff competition in attracting pharmaceutical investments. Steiners sharply criticized the Merz government for undermining confidence in the pharmaceutical sector through these policies.

This development signals significant uncertainty for Germany's pharmaceutical industry, with Roche's cautious stance underscoring broader concerns about the sustainability and attractiveness of Germany as a destination for pharmaceutical investment under current political conditions.